Frequency Therapeutics
300 Technology Square, 8th Floor
Cambridge
Massachusetts
02139
United States
Website: http://www.frequencytx.com/
Email: frequencytx@macbiocom.com
About Frequency Therapeutics
Frequency Therapeutics develops small molecule drugs that activate progenitor cells within the body to restore healthy tissue. Through the transitory activation of these progenitor cells, Frequency enables disease modification without the complexity of genetic engineering. Our lead program re-creates sensory cells in the inner ear to treat chronic noise induced hearing loss, which affects over 30 million people in the U.S. alone. Our platform technology is founded on discoveries in progenitor cell biology by Bob Langer, Sc.D. at MIT and Jeff Karp, Ph.D., at Harvard, with contributions from Xiaolei Yin, Ph.D. and other members of the Karp Lab at Harvard and Brigham & Women's Hospital.YEAR FOUNDED:
2015
LEADERSHIP:
Co-founder and CEO: David Luccino
Co-founder and CSO: Chris Loose, Ph.D.
Co-founder and Vice President, Biology and Regenerative Medicine: Will Mclean, Ph.D.
COO: Michael Jirousek, Ph.D.
CMO: Peter C. Weber, M.D., M.B.A.
Senior Vice President, Drug Development and Technical Operations: Raj Manchanda, Ph.D.
TECHNOLOGY:
Please click here for Frequency Therapeutics' technology.
91 articles about Frequency Therapeutics
-
Frequency Therapeutics Announces Pricing of Initial Public Offering
10/3/2019
Frequency Therapeutics, Inc. announced the pricing of its initial public offering of 6,000,000 shares of common stock at a public offering price of $14.00 per share, for total gross proceeds of approximately $84.0 million, before deducting underwriting discounts and commissions.
-
BioSpace Movers & Shakers, Aug. 23
8/23/2019
Biopharma companies strengthen their senior leadership teams and boards of directors with this week's appointments. -
Frequency Therapeutics Expands Leadership Team
8/22/2019
Frequency Therapeutics, Inc., a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, today announced new appointments to its leadership team.
-
Frequency Therapeutics Completes $62 Million Series C Financing
7/23/2019
Frequency Therapeutics announced the closing of a $62.0 million Series C financing.
-
Astellas and Frequency Therapeutics Enter into License Agreement for FX-322, a Regenerative Treatment Candidate for Hearing Loss
7/17/2019
Astellas Obtains the Exclusive Rights to Develop and Commercialize FX-322 in Ex-U.S. Markets; Frequency Retains U.S. Rights
-
There’s been quite a few small and mid-sized deals announced today. Let’s take a look at four of them.
-
Frequency Therapeutics Announces Positive Phase 1/2 Data for Drug Candidate for Hearing Restoration
4/9/2019
Preliminary clinical data suggests improvement on measures of hearing function
-
Frequency Therapeutics Announces Appointment of Glenn Dubin to Board of Directors
4/4/2019
Frequency Therapeutics announced the addition of Glenn Dubin to the Company’s Board of Directors.
-
For Life Science Companies in the Bay State, Project Onramp Opens up Internship Opportunities
1/29/2019
The Massachusetts Biotechnology Council (MassBio) is taking the lead in fostering the next generation of life science leaders in the Bay State with Project Onramp, an internship program that matches talented students from low-income backgrounds with paid internships in the state’s vibrant life sc... -
Frequency Therapeutics Completes $42 Million Series B Financing
1/7/2019
Joel Marcus, Executive Chairman and Founder of Alexandria Real Estate Equities, Inc. and Alexandria Venture Investments, and Michael Huang, Managing Partner at Taiwania Capital Management, join Board of Directors
-
Frequency Therapeutics to Present at the 37th Annual JP Morgan Healthcare Conference
1/3/2019
Frequency Therapeutics today announced that the Company will present at the upcoming 37th Annual JP Morgan Healthcare Conference in San Francisco on Monday, January 7, 2019
-
In writing literally hundreds of stories this year, two BioSpace writers, Alex Keown and Mark Terry, found certain stories particularly intriguing or impactful. Some of those were such big topics that they were covered over a series of stories. Looking back at 2018, here are their Top 10.
-
After negative reports about after-hours parties that have been deemed disrespectful toward women, and multiple reports about the lack of gender diversity on industry boards of directors, biotech’s biggest trade association is taking action.
-
Frequency Therapeutics Completes Enrollment in Single Dose Safety Trial to Evaluate FX-322, a First-in-Class Drug Candidate for Hearing Restoration
10/4/2018
Frequency Therapeutics today announced the completion of enrollment in the single dose safety trial to evaluate FX-322, a first-in-class drug candidate for hearing restoration from the company’s Progenitor Cell Activation (PCA) Regeneration platform.
-
Frequency Therapeutics Strengthens Scientific Advisory Board with Addition of Leading Experts in Neurology, Stem Cell and Regenerative Medicine
8/14/2018
Robin Franklin, Ph.D., Professor of Stem Cell Medicine at the Wellcome Trust-MRC Cambridge Stem Cell Institute, and Sheng Ding, Ph.D., William K. Bowes, Jr. Distinguished Investigator and Professor at Gladstone Institute
-
Frequency Therapeutics Initiates Phase 1/2 Single Dose Clinical Trial to Evaluate FX-322, a First-in-Class Drug Candidate for Hearing Restoration
8/7/2018
Trial marks the first time a potential progenitor cell activator will be tested in adult patients with stable sensorineural hearing loss
-
U.S. Department of Defense Awards $2M Grant to Frequency Therapeutics
5/30/2018
Research Award will support translational preclinical and early-stage clinical research to address hearing dysfunction resulting from military service-related injuries
-
Frequency Therapeutics to Lead Featured Session at the American Academy of Audiology Annual Conference
4/18/2018
Frequency Therapeutics will lead a Featured Session at the American Academy of Audiology (AAA) Annual Conference taking place April 18 to 21 in Nashville, TN.
-
Science Magazine Recognizes Frequency Therapeutics’ PCA Regeneration Technology as a Breakthrough in Regenerative Medicine
3/20/2018
Frequency Co-founder Will McLean, Ph.D., Named a Finalist Awardee for the Sartorius & Science Prize for Regenerative Medicine & Cell Therapy
-
Frequency Therapeutics Welcomes Former Otonomy CSO as Executive Vice President of Clinical Development
3/12/2018
Leading clinical development executive joins as company prepares for Phase 2 clinical trials in hearing restoration